Xencor (XNCR) Competitors $8.41 +0.97 (+13.04%) Closing price 04:00 PM EasternExtended Trading$8.41 0.00 (0.00%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. AGIO, DNLI, GLPG, IDYA, SRPT, BLTE, HRMY, IRON, MESO, and ARQTShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), Galapagos (GLPG), IDEAYA Biosciences (IDYA), Sarepta Therapeutics (SRPT), Belite Bio (BLTE), Harmony Biosciences (HRMY), Disc Medicine (IRON), Mesoblast (MESO), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Agios Pharmaceuticals Denali Therapeutics Galapagos IDEAYA Biosciences Sarepta Therapeutics Belite Bio Harmony Biosciences Disc Medicine Mesoblast Arcutis Biotherapeutics Agios Pharmaceuticals (NASDAQ:AGIO) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability. Which has more risk and volatility, AGIO or XNCR? Agios Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Is AGIO or XNCR more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Xencor's net margin of -121.52%. Agios Pharmaceuticals' return on equity of -3.49% beat Xencor's return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,590.42% -3.49% -3.23% Xencor -121.52%-25.75%-18.19% Which has stronger earnings and valuation, AGIO or XNCR? Agios Pharmaceuticals has higher earnings, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$36.50M61.76$673.72M$11.003.53Xencor$146.93M4.08-$232.62M-$2.40-3.50 Do analysts recommend AGIO or XNCR? Agios Pharmaceuticals presently has a consensus target price of $56.33, suggesting a potential upside of 45.19%. Xencor has a consensus target price of $23.71, suggesting a potential upside of 181.98%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to AGIO or XNCR? In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Xencor. MarketBeat recorded 4 mentions for Agios Pharmaceuticals and 3 mentions for Xencor. Agios Pharmaceuticals' average media sentiment score of 0.93 beat Xencor's score of 0.50 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAgios Pharmaceuticals beats Xencor on 9 of the 13 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$599.83M$2.80B$5.82B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-3.5022.6131.1525.96Price / Sales4.08751.87474.77122.97Price / CashN/A173.2237.1558.38Price / Book0.975.869.116.39Net Income-$232.62M$31.83M$3.26B$265.56M7 Day Performance9.51%1.80%2.12%1.98%1 Month Performance-8.59%4.36%5.13%1.33%1 Year Performance-49.55%11.45%31.25%21.15% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.5274 of 5 stars$8.41+13.0%$23.71+182.0%-57.2%$599.83M$146.93M-3.50280News CoverageAnalyst ForecastAGIOAgios Pharmaceuticals4.3577 of 5 stars$37.45+1.2%$56.33+50.4%-18.9%$2.15B$36.50M3.40390DNLIDenali Therapeutics4.204 of 5 stars$14.82+0.8%$33.62+126.8%-39.1%$2.15B$330.53M-5.29430News CoverageGLPGGalapagos0.1338 of 5 stars$32.91+1.4%$25.33-23.0%+26.6%$2.14B$275.61M0.001,310IDYAIDEAYA Biosciences4.519 of 5 stars$24.75+1.7%$48.09+94.3%-38.0%$2.13B$7M-6.5380Positive NewsSRPTSarepta Therapeutics4.6432 of 5 stars$20.99-3.8%$43.63+107.8%-86.0%$2.13B$1.90B-24.131,372Trending NewsAnalyst ForecastShort Interest ↑BLTEBelite Bio2.5894 of 5 stars$64.95-2.5%$96.67+48.8%+32.5%$2.12BN/A-41.9010HRMYHarmony Biosciences4.5893 of 5 stars$36.41-1.2%$51.00+40.1%+1.3%$2.12B$714.73M11.75200Positive NewsIRONDisc Medicine3.4812 of 5 stars$58.84-1.7%$96.18+63.5%+21.2%$2.08BN/A-13.1630MESOMesoblast2.1102 of 5 stars$15.93-2.0%$18.00+13.0%+133.0%$2.08B$5.67M0.0080News CoverageUpcoming EarningsARQTArcutis Biotherapeutics1.8832 of 5 stars$16.74-0.9%$19.80+18.3%+89.3%$2.03B$196.54M-22.32150Positive News Related Companies and Tools Related Companies Agios Pharmaceuticals Alternatives Denali Therapeutics Alternatives Galapagos Alternatives IDEAYA Biosciences Alternatives Sarepta Therapeutics Alternatives Belite Bio Alternatives Harmony Biosciences Alternatives Disc Medicine Alternatives Mesoblast Alternatives Arcutis Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access